Contact
searchSearch
HMP Global
Login

Multiple Myeloma News

Conference Coverage
Racial and Ethnic Differences in Clinical Outcomes Among Patients With Multiple Myeloma Treated with CAR T Therapy
12/10/2022
Craig Ostroff
At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...
At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...
At the 64th ASH Annual Meeting...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
No Evidence That BCMA Expression Is Completely Lost Following Belamaf Treatment in Patients With RRMM
12/10/2022
Craig Ostroff
In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...
In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...
In a presentation at the 64th...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
Updated, Longer-term Efficacy Data Following Subsequent Therapy in ICARIA-MM
12/10/2022
Craig Ostroff
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Paul G Richardson, MD, and...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
A 12-Gene Signature Accurately Predicts Progression From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
12/10/2022
Craig Ostroff
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Speaking at the 64th ASH Annual...
12/10/2022
Journal of Clinical Pathways
News
Belantamab in Combination With Dexamethasone Demonstrates Good Clinical Activity in Triple-Class Relapsed/Refractory MM
09/12/2022
Yvette C. Terrie, BS Pharm, RPh
Outcomes in relapsed/refractory myeloma remain poor, and novel therapy approaches are necessary, according to findings from a study published in Clinical Lymphoma, Myeloma & Leukemia.
Outcomes in relapsed/refractory myeloma remain poor, and novel therapy approaches are necessary, according to findings from a study published in Clinical Lymphoma, Myeloma & Leukemia.
Outcomes in relapsed/refractory...
09/12/2022
Journal of Clinical Pathways
News
Clinical Significance of CTCs in Staging of Newly Diagnosed Transplant-Eligible Patients With Multiple Myeloma
08/16/2022
Yvette C. Terrie, BS Pharm, RPh
The assessment of circulating tumor cells in peripheral blood outperformed quantification of bone marrow plasma cells and the discovery of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible...
The assessment of circulating tumor cells in peripheral blood outperformed quantification of bone marrow plasma cells and the discovery of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible...
The assessment of circulating...
08/16/2022
Journal of Clinical Pathways
News
Exploring Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed MM
08/11/2022
Yvette C. Terrie, BS Pharm, RPh
Patients with newly diagnosed multiple myeloma treated with combination regimen of bortezomib, lenalidomide, and dexamethasone induction followed by early autologous stem cell transplantation (ASCT) may not have a greater occurrence of...
Patients with newly diagnosed multiple myeloma treated with combination regimen of bortezomib, lenalidomide, and dexamethasone induction followed by early autologous stem cell transplantation (ASCT) may not have a greater occurrence of...
Patients with newly diagnosed...
08/11/2022
Journal of Clinical Pathways
News
Systematic Review Protocol Explores Impact of Bortezomib in Multiple Myeloma Treatment
07/27/2022
Ellen Kurek
Researchers detailed their systematic review protocol which will aim to evaluate the effects of bortezomib on the overall survival, progression-free survival, overall response rate, time to next treatment, health-related quality of life,...
Researchers detailed their systematic review protocol which will aim to evaluate the effects of bortezomib on the overall survival, progression-free survival, overall response rate, time to next treatment, health-related quality of life,...
Researchers detailed their...
07/27/2022
Journal of Clinical Pathways
News
Comparative Effectiveness of Ciltacabtagene Autoleucel vs Physician’s Choice of Therapy for Relapsed or Refractory Multiple Myeloma
05/16/2022
Ellen Kurek
Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.
Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.
Ciltacabtagene autoleucel...
05/16/2022
Journal of Clinical Pathways
News
Cost and Utilization of Daratumumab in Patients With Multiple Myeloma
05/02/2022
Ellen Kurek
In patients with multiple myeloma, daratumumab is utilized more frequently than the FDA-recommended dosing, which may lead to higher treatment costs.
In patients with multiple myeloma, daratumumab is utilized more frequently than the FDA-recommended dosing, which may lead to higher treatment costs.
In patients with multiple...
05/02/2022
Journal of Clinical Pathways
JCP March/April 2025

Current Issue

April 2025
Volume 11
Issue 2
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use